Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) – Investment analysts at Wedbush issued their Q1 2024 EPS estimates for Adicet Bio in a research report issued to clients and investors on Thursday, March 16th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.80) for the quarter. Wedbush has a “Outperform” rating and a $30.00 price target on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($1.94) per share. Wedbush also issued estimates for Adicet Bio’s Q2 2024 earnings at ($0.83) EPS, Q3 2024 earnings at ($0.87) EPS, Q4 2024 earnings at ($0.91) EPS and FY2027 earnings at $6.39 EPS.
Other equities research analysts also recently issued reports about the stock. StockNews.com assumed coverage on shares of Adicet Bio in a research note on Thursday. They issued a “sell” rating on the stock. JMP Securities reissued a “buy” rating and set a $19.00 price target on shares of Adicet Bio in a research note on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of Adicet Bio in a research note on Thursday. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $27.50.
Adicet Bio Price Performance
Institutional Trading of Adicet Bio
Institutional investors have recently bought and sold shares of the company. RTW Investments LP lifted its stake in shares of Adicet Bio by 7.3% in the 3rd quarter. RTW Investments LP now owns 4,241,472 shares of the company’s stock worth $60,314,000 after purchasing an additional 290,191 shares during the period. EcoR1 Capital LLC bought a new stake in Adicet Bio during the 4th quarter worth approximately $31,833,000. Cowen AND Company LLC raised its stake in Adicet Bio by 28.7% during the 4th quarter. Cowen AND Company LLC now owns 3,143,608 shares of the company’s stock worth $28,104,000 after acquiring an additional 700,362 shares during the period. BlackRock Inc. raised its stake in Adicet Bio by 14.1% during the 3rd quarter. BlackRock Inc. now owns 2,109,787 shares of the company’s stock worth $30,003,000 after acquiring an additional 260,705 shares during the period. Finally, RA Capital Management L.P. bought a new stake in Adicet Bio during the 3rd quarter worth approximately $29,284,000.
Insider Transactions at Adicet Bio
In other news, CTO Don Healey sold 4,533 shares of the company’s stock in a transaction dated Wednesday, February 15th. The shares were sold at an average price of $7.57, for a total value of $34,314.81. Following the sale, the chief technology officer now directly owns 66,568 shares of the company’s stock, valued at approximately $503,919.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 29.20% of the company’s stock.
Adicet Bio Company Profile
Adicet Bio, Inc is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
- Get a free copy of the StockNews.com research report on Adicet Bio (ACET)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.